Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MYX2468
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Organovo Holdings
Deal Size : $114.0 million
Deal Type : Series A Financing
Novo Holdings Leads £90M Financing for Myricx Bio ADC Payload Class
Details : The financing aims to fund the advancement of Myricx's proprietary pipeline of N-Myristoyltransferase inhibitor MYX2468 for the treatment of neoplasms.
Product Name : MYX2468
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
July 07, 2024
Lead Product(s) : MYX2468
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Organovo Holdings
Deal Size : $114.0 million
Deal Type : Series A Financing